ROVIELLO, GIANDOMENICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.057
EU - Europa 6.899
AS - Asia 4.194
SA - Sud America 588
OC - Oceania 137
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 2
Totale 23.941
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.986
RU - Federazione Russa 2.978
HK - Hong Kong 1.317
IT - Italia 1.144
SG - Singapore 1.117
CN - Cina 1.011
PL - Polonia 842
IE - Irlanda 741
BR - Brasile 539
SE - Svezia 306
IN - India 257
DE - Germania 221
AU - Australia 137
ID - Indonesia 135
FR - Francia 128
FI - Finlandia 125
GB - Regno Unito 94
JO - Giordania 89
VN - Vietnam 72
ES - Italia 64
CH - Svizzera 61
TR - Turchia 58
NL - Olanda 56
AT - Austria 41
CA - Canada 36
CI - Costa d'Avorio 36
JP - Giappone 21
LU - Lussemburgo 19
BD - Bangladesh 18
UA - Ucraina 18
AE - Emirati Arabi Uniti 16
AR - Argentina 14
BE - Belgio 14
IQ - Iraq 13
MX - Messico 12
UZ - Uzbekistan 12
CZ - Repubblica Ceca 11
ZA - Sudafrica 11
EC - Ecuador 10
PT - Portogallo 9
PK - Pakistan 8
AZ - Azerbaigian 7
PE - Perù 7
LT - Lituania 6
SA - Arabia Saudita 6
TT - Trinidad e Tobago 6
BB - Barbados 5
NO - Norvegia 5
TN - Tunisia 5
VE - Venezuela 5
CO - Colombia 4
IL - Israele 4
MA - Marocco 4
NP - Nepal 4
PY - Paraguay 4
RS - Serbia 4
GR - Grecia 3
GT - Guatemala 3
JM - Giamaica 3
KE - Kenya 3
KG - Kirghizistan 3
MY - Malesia 3
OM - Oman 3
PH - Filippine 3
TH - Thailandia 3
BO - Bolivia 2
CL - Cile 2
DZ - Algeria 2
GE - Georgia 2
HN - Honduras 2
KR - Corea 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
PA - Panama 2
BG - Bulgaria 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EU - Europa 1
HR - Croazia 1
IR - Iran 1
LB - Libano 1
LI - Liechtenstein 1
MN - Mongolia 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
PS - Palestinian Territory 1
SN - Senegal 1
TJ - Tagikistan 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 23.941
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.484
Fairfield 1.595
Hong Kong 1.118
Singapore 834
Warsaw 834
Ashburn 812
Dublin 738
Woodbridge 734
Seattle 679
Houston 575
Cambridge 565
Wilmington 523
Lawrence 334
Altamura 332
Beijing 242
Hefei 230
Moscow 225
Ann Arbor 203
Chandler 199
Florence 172
Princeton 171
Boston 158
Jakarta 132
Melbourne 129
Mumbai 111
Munich 99
San Diego 79
Shanghai 79
Bengaluru 77
Helsinki 65
Rome 62
Barcelona 57
Bern 57
Milan 56
Buffalo 51
Paris 50
Dong Ket 46
São Paulo 44
Bremen 41
New York 41
Los Angeles 39
Medford 39
Norwalk 37
Abidjan 36
Vienna 33
Turku 31
West Jordan 31
Falls Church 29
Boardman 27
Lappeenranta 27
London 26
Pune 25
Yubileyny 25
Frankfurt am Main 24
Kent 22
Adana 20
Arezzo 20
Toronto 19
Hillsboro 16
Brasília 13
Brussels 13
Chicago 13
Guangzhou 13
Shenzhen 13
Curitiba 12
Rio de Janeiro 12
Roodt-sur-Syre 12
The Dalles 12
Belo Horizonte 11
Siena 11
Tashkent 11
Brescia 10
Istanbul 10
Padova 10
Roubaix 10
Dallas 9
Redmond 9
Washington 9
Wuhan 9
Zhengzhou 9
Andover 8
Decatur 8
Dhaka 8
Düsseldorf 8
Johannesburg 8
Phoenix 8
San Francisco 8
Tokyo 8
Baku 7
Chennai 7
Ho Chi Minh City 7
Lisbon 7
Mexico City 7
New Bedfont 7
Olomouc 7
Romola 7
Sydney 7
Turin 7
Xuzhou 7
Baghdad 6
Totale 16.937
Salva come PNG Salva come JPEG
Nome #
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience 247
Darolutamide in hormone-sensitive and castration-resistant prostate cancer 183
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 159
Is there still a place for docetaxel rechallenge in prostate cancer? 156
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 153
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 152
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer 151
Isolated Testicular Metastasis from Prostate Cancer 147
Adjuvant treatment for EGFR-mutated non-small cell lung cancer: Do we have a major breakthrough? 140
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer 139
A husband and a wife with simultaneous presentation of glioblastoma multiforme: a case report 139
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience 137
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 137
Ntrk gene fusion detection in atypical spitz tumors 133
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now? 132
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer? 130
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 129
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 128
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015 128
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 128
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study 128
Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer 128
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer 127
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223 126
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status 126
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate 125
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer 124
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin 124
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer 122
Bevacizumab in small cell lung cancer 122
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer 120
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 119
Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14) 119
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival 118
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 116
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 116
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 116
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 115
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 114
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights 114
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 112
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 111
Role of ATP-binding cassette transporters in cancer initiation and progression 111
Current status and future perspectives in HER2 positive advanced gastric cancer 110
Advances in systemic therapy for metastatic breast cancer: future perspectives 110
Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer 110
Robotic approach with neoadjuvant chemotherapy in adult Wilms' tumor: A feasibility study report and a systematic review of the literature 109
Inflammation in Urological Malignancies: The Silent Killer 109
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 109
Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis 109
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 108
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 107
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer 107
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 107
Acute Massive and Submassive Pulmonary Embolism: Preliminary Validation of Aspiration Mechanical Thrombectomy in Patients with Contraindications to Thrombolysis 107
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 107
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 106
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 106
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer 106
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study 106
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 105
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 105
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 105
Surgical management of advanced gastric cancer: An evolving issue 105
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 104
Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review 104
28. Role of neoadjuvant chemotherapy with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for treatment of primary ovarian cancer with peritoneal carcinomatosis 104
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 104
Immunotherapy-based combinations versus standard first-line and hypothyroidism risk 104
Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19) 104
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 103
Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity following Chemotherapy 102
In reply to Egger et al.: Lack of benefit from adjuvant postoperative radiotherapy and issues raised about upfront management of high- and very-high-risk prostate cancer patients 102
Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma 101
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study 101
Prostate Cancer Characteristics in Renal Transplant Recipients: A 25-Year Experience From a Single Centre 101
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review 100
ALTERTASTE: improving food pleasure and intake of oncology patients receiving chemotherapy 100
REBECA trial: A new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer 100
Immune checkpoint inhibitors in urothelial bladder cancer: State of the art and future perspectives 100
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 99
Advances in systemic therapy for malignant mesothelioma: future perspectives 99
The distinctive nature of adenocarcinoma of the lung 99
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 99
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors 98
Gastric and colonic metastasis from NSCLC A very unusual case report 98
Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients 97
The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients 97
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 97
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 96
Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis 96
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials 96
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials 96
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy 95
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study 95
Familial aggregation of gastric cancer with microsatellite instability** 95
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 95
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 95
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? 95
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials 94
Totale 11.519
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.148
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.148
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.191 225 219 30 474 131 122 98 73 313 164 222 120
2021/20221.018 9 11 96 29 29 107 11 137 87 38 107 357
2022/20232.731 269 770 69 162 36 447 491 110 179 51 53 94
2023/20241.637 49 90 273 79 102 162 56 299 62 219 117 129
2024/202512.158 481 1.276 692 1.629 3.083 1.541 316 391 898 403 563 885
2025/2026317 317 0 0 0 0 0 0 0 0 0 0 0
Totale 24.390